Webinar: The Growing Application of Spatial Multi-Omics for the Identification of Biomarkers Opens New Doors in Cancer Drug Development

SUMMARY

The advent of multi-omics is allowing to probe the more complex and transient molecular changes that underpin the course of disease and response to treatment. Spatial omics approaches have the advantage of dissecting cellular dynamics and heterogeneity, whereas traditional bulk technologies are limited to individual/population-level investigation. This has far-reaching implications for drug development giving us the potential to spot a new drug target in the context of the disease, anticipate toxicity and decipher drug mechanism of action at the single cell level. Ultimately, spatial multi-omics is an enabler for predictivity and we can use spatial-biomarkers to predict what a drug molecule could do in a cell and its environmental cells with far greater certainty.


As part of Imabiotech’s webinar series, Corinne Ramos, Innovation director, discussed the use of Fluidigm’s Hyperion platform (Imaging Mass Cytometry Services) and GeoMx® NanoString platform for biomarkers discovery and predicting response to a given treatment. This webinar also highlighted the advantage of using such high multiplex technologies in routine analysis to obtain faster throughput in a GLP-like environment.

THURSDAY, FEBRUARY 10TH 2022

  • EUROPE TIME: 4PM CET
  • USA TIME: 10AM EST

Conference animated by :

Corinne Ramos (Director of Innovation & Marketing, ImaBiotech)




Search news